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0929-6646/Copyright ª 2015, ElsevierBackground/purpose: Full-dose sirolimus (SRL) therapy without a calcineurin inhibitor (CNI) re-
duces the incidence of malignancy after renal transplantation, but with significant side ef-
fects. We hypothesized that de novo therapy with low-dose SRL combined with a CNI could
still prevent cancer in renal transplant recipients.
Methods: A retrospective caseecontrol study was performed to assess the cancer incidence
among renal transplant patients who had undergone surgery in our transplant centers between
January 2000 and June 2012. Patients who received low-dose SRL and a CNI (SRL group,
n Z 189) were compared with patients receiving conventional CNI-based therapy in the same
hospitals (Conventional group, n Z 271).
Results: The 5-year graft and patient survival rates were comparable between the two groups.
Seven patients in the SRL group and 24 patients in the Conventional group developed malig-
nancies during mean follow-up periods of 68.2  37.5 months and 81.7  51.4 months, respec-
tively. The cancer incidence at 5 years was significantly lower in the SRL group (1.9%), than
that in the Conventional group (6.7%; p Z 0.04). By multivariate analyses, SRL therapydata of this article was accepted and presented at the World Transplant Congress, San Francisco,
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Cancer avoidance after renal transplantation 527(pZ 0.04), male sex (pZ 0.04), and younger age (pZ 0.01) were significantly associated with
a lower risk of malignancy after kidney transplantation.
Conclusion: De novo therapy with low-dose SRL combined with a CNI was associated with
reduced risk of post-transplant cancer in renal transplant recipients. De novo cancer preven-
tion using a low-dose proliferation signal inhibitor such as SRL could be effective for renal
transplant recipients.
Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Renal transplantation is associated with an increased risk of
cancer, which is probably caused by prolonged immuno-
suppression due to the use of calcineurin inhibitors
(CNIs).1,2 Research and clinical studies have reported that
sirolimus (SRL), a macrocyclic lactone inhibitor of the
mammalian target of rapamycin (mTOR) signaling pathway,
exerts both anticancer and immunosuppressive effects.3e6
SRL therapy, after early CNI withdrawal, reduced the inci-
dence of both skin and nonskin malignancies in renal
transplant patients after 5 years.7,8 Furthermore, SRL pre-
vented secondary skin cancer in high-risk renal transplant
recipients.9,10 However, SRL-related adverse events
occurred frequently, sometimes resulting in the discontin-
uation of SRL treatment. For example, Campbell et al11
reported that 46.2% of patients taking full-dose SRL
(trough levels > 8 ng/mL) without a CNI discontinued
treatment during their follow-up. We reported recently
that low-dose SRL (targeting trough levels of 4e8 ng/mL)
combined with either tacrolimus (TAC) or cyclosporine
(CsA) CNIs might have a reduced SRL discontinuation rate
(15%).12
Although low-dose SRL and CNI combinations reduce the
recurrence of hepatocellular carcinoma after liver trans-
plantation, the efficacy of this drug combination has not
yet been assessed thoroughly in renal transplant pa-
tients.13,14 Previously, Kreis et al15 demonstrated that,
compared with placebo, the combination of SRL and CsA
resulted in a significantly lower 2-year incidence of skin
cancer. In addition, a low incidence of malignancy (mostly
skin tumors) was reported in SRL/CsA-treated renal trans-
plant recipients when analyzed using the Surveillance,
Epidemiology, and End Results (SEER) database of the
general United States population.16 In a large, long-term
study performed by Wimmer et al,17 mTOR inhibitor-
based regimens did not significantly reduce the risk of de
novo malignancies after renal transplantation. By contrast,
Kauffman et al5 used the Organ Procurement and Trans-
plantation Network/United Network for Organ Sharing
(OPTN/UNOS) database to document the association be-
tween mTOR inhibitors and reduced post-transplant ma-
lignancies, but did not report the timing and doses of SRL
used.
A primary dose of 2 mg/d of SRL is commonly used in
combination with a CNI.18,19 We previously performed
several prospective trials to assess the efficacy of de novo
SRL therapy (2 mg/d, trough levels of 4e8 ng/mL) against
acute rejection.12,20e22 We hypothesized that low-dose SRL
and a CNI might help prevent cancer. Therefore, weperformed a caseecontrol study to assess the cancer inci-
dence in long-term renal transplant patients treated with
or without de novo SRL.
Patients and methods
Study group
A caseecontrol study was performed to assess the benefi-
cial effect of low-dose SRL and a CNI on cancer prevention
after renal transplantation. Data from renal transplant
patients who met the criterion of our previous studies for
SRL de novo therapy were collected and reviewed. We
excluded: patients who had received antibody induction
therapy or multiple solid organ transplants; patients who
had tested positive for hepatitis B virus surface antigen or
anti-hepatitis C virus antibodies; and patients with ABO
incompatibility or positive lymphocytotoxicity.12,20e22 Pa-
tients with < 6 months of follow-up, secondary transplants,
or pretransplant cancers were also excluded. The outcomes
of patients who underwent renal transplantation with the
combination therapy of low-dose SRL and a CNI between
January 2000 and June 2012 (SRL group) were compared
with outcomes of those who received conventional CNI-
based regimens in the same transplant centers (Conven-
tional group). The clinical and research activities reported
comply with the ethical standards laid down in the Decla-
ration of Helsinki and its later amendments.
Immunosuppressive regimens
The immunosuppressive regimens in the SRL group included
SRL, corticosteroids, and a CNI (either CsA or TAC). SRL was
administered at a loading dose of 6 mg within 48 hours after
graft reperfusion, followed by amaintenance dose of 2 mg/d.
The initial target trough levels of the CNIs were 100e200 ng/
mL for CsA and 4e8 ng/mL for TAC.22 The trough levels of SRL
were measured regularly and adjusted if side effects
occurred. The target blood levels at 12 months were
50150 ng/mL for CsA, 36 ng/mL for TAC, and 48 ng/mL
for SRL. In the Conventional group, the CNI doses were
initially adjusted to the target trough levels of 200400 ng/
mL for CsA and 816 ng/mL for TAC. The target blood levels at
12 months were 100200 ng/mL for CsA and 58 ng/mL for
TAC. In addition, mycophenolate mofetil or mycophenolate
sodium was prescribed at an initial dose of 12 g/d or
7201440 mg/d, respectively. White blood cell counts were
maintained between 4  109/L and 6  109/L unless intoler-
ance developed or the maximum dose was reached.









42.5  13.0 40.5  13.5 0.10
Sex (M:F) 95:94 125:146 0.39
Donor type (D:L) 139:50 168:103 0.01
HLA mismatches 3.2  1.5 2.6  1.4 <0.001
Initial CNI (TAC:CsA) 155:34 152:119 <0.001





5-y graft survival 86.5% 84.7% 0.25
5-y patient survival 97.0% 97.5% 0.43
5-y cancer incidence 1.9% 6.7% 0.04
Follow-up (mo) 68.2  37.5 81.7  51.4 0.002
CNI Z calcineurin inhibitor; CsA Z cyclosporine;
D Z deceased; F Z female; L Z living; M Z male;
SRL Z sirolimus; TAC Z tacrolimus.
a Two-tailed Fisher’s exact test was used for categorical var-
iables; two-tailed unpaired t-test was used for continuous var-
iables; log-rank test was used for survival analysis.
Figure 1 KaplaneMeier estimates of the cumulative cancer
incidence (intent-to-treat analysis). The sirolimus (SRL) group
exhibited a significantly lower risk of malignancy than the
Conventional group (p Z 0.04).
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lone and oral prednisolone, were administered, consistent
with standard practices. The dose of prednisolone was
reduced to 2.55 mg/d at 12 months and could then be
discontinued if significant side effects were reported. To
prevent cytomegalovirus disease, valganciclovir (450 mg/d)
was administered to patients with a functioning graft for 3
months, unless the patient had leukopenia.
Statistical analyses
Intent-to-treat analyses were performed using NCSS 2008
for Windows software (Kaysville, UT, USA). Graft and pa-
tient survival, and cancer incidence were estimated using
the KaplaneMeier method. For patients with multiple
cancers, only the first cancer was recorded for statistical
analyses. All values were expressed as the mean  standard
deviation. Unpaired two-tailed t tests and Fisher’s exact
tests were used for normally distributed continuous vari-
ables and categorical variables, respectively. Univariate
analysis using the log-rank test was used to determine the
statistical significance of the effects of SRL de novo ther-
apy, recipient sex, CNI (CsA or TAC) therapy, donor type,
and acute rejection on cancer incidence. Cox regression
analysis was used to assess the statistical significance of
recipient age at transplantation and HLA mismatches on
cancer occurrence. Finally, multivariate Cox’s regression
analysis was employed to examine the independent effect




Patient demographics and outcomes of the SRL and Con-
ventional groups are summarized in Table 1. The mean ages
of patients in the SRL (42.5  13.0 years) and Conventional
groups (40.5  13.5 years) at transplantation were com-
parable (pZ 0.10). There were more female patients in the
Conventional group (53.9%, 146/271) than in the SRL group
(49.7%, 94/189), but the difference was statistically insig-
nificant (p Z 0.39). The number of deceased-donor trans-
plants (73.5%, 139/189) included in the SRL group was
higher than that included in the Conventional group (62.0%,
168/271; p Z 0.01). The mean number of HLA mismatches
between donors and recipients was also higher in the SRL
group (3.2  1.5 vs. 2.6  1.4, p < 0.001). In addition, the
number of patients in the SRL group who received TAC
(82.0%, 155/189) was higher than the number of patients in
the Conventional group who received TAC (56.1%, 152/271;
p < 0.001).
Transplant outcomes
The 5-year graft and patient survival rates of the two
groups were comparable, although there was a lower inci-
dence of acute rejection at 1 year in the SRL group than
that in the Conventional group (15.3% vs. 19.2%; pZ 0.32).
Seven patients in the SRL group and 24 patients in theConventional group developed malignancies during mean
follow-up periods of 68.2  37.5 months and 81.7  51.4
months, respectively. During the follow-up period, 22 SRL
group patients stopped taking SRL at 2 years (11.6%, 22/
189).12 The incidences of de novo cancers at 5 years post-
transplantation in the SRL and Conventional groups were
1.9% and 6.7%, respectively (Fig. 1). The difference in post-
transplant cancer incidence between the two groups was
statistically significant (p Z 0.04).
Urothelial carcinoma was the most common post-
transplant malignancy, accounting for 57.1% (4/7) and
54.2% (13/24) of the pathological diagnoses in the SRL and
Conventional groups, respectively. Skin cancer was rela-
tively rare in our study population: only one and two cases
Table 3 Univariate analyses of prognostic factors for
cancer incidence.





Sirolimus therapy Yes 189 1.9 0.04
No 271 6.7




TAC 307 3.7 0.23
CsA 153 6.1
Acute rejection Yes 81 1.5 0.61
No 379 5.4







Age at transplantation 0.04 0.02 1.04 0.02
HLA mismatches 0.12 0.14 0.89 0.38
Follow-up (mo) 0.00 0.00 1.00 0.75
CsA Z cyclosporine; TAC Z tacrolimus.
Cancer avoidance after renal transplantation 529of nonmelanoma skin cancer were reported in the SRL and
Conventional groups, respectively. There were two cases of
post-transplant lymphoproliferative disease in the Con-
ventional group but none in the SRL group. Even though
patients with hepatitis B and C viral infections were
excluded, there was one case of hepatocellular carcinoma
in the Conventional group. The pathological diagnoses of
post-transplant malignancy are summarized by immuno-
suppressive regimens in Table 2.
Univariate and multivariate analyses
Univariate analyses were performed to identify risk factors
for post-transplant de novo malignancies. Data revealed
that SRL de novo therapy (p Z 0.04), sex (p Z 0.04), and
age at transplantation (p Z 0.02) were significant prog-
nostic factors. Patients in the SRL group had a significantly
lower risk of post-transplant cancer than those in the
Conventional group. Interestingly, male patients were
found to have lower incidence of cancer after renal trans-
plantation than female patients. Besides, the risk ratio of
post-transplant cancer was found to be 1.038 per year of
increased age in the univariate analysis. Donor type, CNI
therapy, acute rejection, and follow-up duration were not
significantly associated with the development of post-
transplant cancer. Results of the univariate analyses are
shown in Table 3. Cox’s multivariate regression analysis
revealed that de novo SRL therapy (p Z 0.04), sex
(p Z 0.04), and age at transplantation (p Z 0.01) were
significant factors for post-transplant malignancies. De
novo SRL therapy (risk ratio Z 0.38) and male sex (risk
ratio Z 0.43) were independently associated with
decreased risk of cancer development, whereas older age
at transplantation increased the risk of malignant tumors by
a ratio of 1.04 per year (Table 4).
Risk factors for urothelial carcinoma
Since urothelial carcinoma accounted for most cancer pa-
thology, survival analyses were further conducted to reveal








Urothelial carcinoma 4/7 (57.1) 13/24 (54.2)
Skin cancer (nonmelanotic) 1/7 (14.3) 2/24 (8.3)
PTLD 0/7 (0.0) 2/24 (8.3)
Gastrointestinal carcinoma 1/7 (14.3) 1/24 (4.2)
Breast cancer 1/7 (14.3) 1/24 (4.2)
Hepatocellular carcinoma 0/7 (0.0) 1/24 (4.2)
Gynecological cancer 0/7 (0.0) 1/24 (4.2)
Others 0/7 (0.0) 3/24 (12.5)
Data are presented as n/N (%).
PTLD Z post-transplant lymphoproliferative disease.
a In case of multiple cancers, only the first cancer was
counted.By log-rank tests and Cox’s regression, female sex was
identified as the only risk factor (p Z 0.03) for post-
transplant urothelial carcinoma. Age at transplantation
and SRL therapy were not significant factors for urothelial
carcinoma, possibly because of inadequate patient and
cancer numbers.
Discussion
Determining the minimal dosage of SRL that could effec-
tively prevent post-transplant cancers is worthwhile. Pre-
vious studies reported that high-dose SRL (trough levels >
8 ng/mL) without CNI was associated with an increased
incidence of adverse events, which could lead to the
discontinuation of SRL treatment. Nevertheless, the effects
of SRL on cancer prevention were evident in patients who
received SRL-based therapy initiated early post-trans-
plantation.7,11 This mTOR inhibitor could be regarded as an
agent for de novo cancer prevention, akin to ganciclovir for
the prevention of cytomegalovirus, if the minimal effective
dose of mTOR inhibitors could be identified. There might be
an inverse relationship between the dose of mTOR inhibitor
and the incidence of cancer after transplantation. Howev-
er, the efficacy of SRL was difficult to assess in retrospec-
tive studies that included long-term follow-up of patients
who were converted to variable doses of SRL at different
time points post-transplantation.23 In addition, SRL was
only transiently effective, or even ineffective, in treating
renal transplant recipients with severe Kaposi’s sarcoma or
urothelial carcinoma.24,25 De novo SRL therapy at 2 mg/d,
which targeted a trough level of 4e8 ng/mL, could reduce
the incidence of post-transplant malignancies in the cur-
rent study, even in combination with a CNI.
The reduced cancer incidence in the current study might
result from the antiproliferative effect of SRL, as well as
the reduced doses of CNIs. A previous study reported that
patients receiving CNI-based therapies had a significantly
Table 4 Multivariate Cox’s regression analysis of the factors with statistical significance in the univariate analysis.
Cox’s regression Regression coefficient Standard error Risk ratio Lower 95% CL Upper 95% CL p
Sirolimus therapy 0.96 0.46 0.38 0.16 0.95 0.04
Male sex 0.85 0.41 0.43 0.19 0.96 0.04
Age at transplantation 0.04 0.02 1.04 1.01 1.08 0.01
CL Z confidence limit.
530 K.-H. Chen et al.higher risk of post-transplant cancer than those treated
with azathioprine and steroids (ST).2 Campistol et al7 re-
ported that immunosuppressive regimens converted from
combined SRL (troughs of 515 ng/mL) with CsA and ST to
high-dose SRL (troughs > 15 ng/mL) with ST reduced the
rates of nonskin cancer from 9.6% to 4.0% at 5 years.
However, the overall 5-year cancer incidence (1.9%)
observed in our SRL group, which also included patients
receiving the SRL þ CsA þ ST regimen, was much lower than
the risk of nonskin cancer in patients treated with SRL þ ST
(4.0%) in the study by Campistol et al.7 This suggests that a
SRL þ CsA þ ST regimen could still be effective for pre-
venting nonskin cancer.
The pathological diagnoses of post-transplant malig-
nancies vary among different countries. Nonmelanoma
skin cancer and lymphoproliferative disorders are preva-
lent in Western, but not Asian, countries.16,26 By contrast,
urothelial carcinoma is relatively common among Asian
renal transplant patients, especially when those with viral
hepatitis are excluded.27 The underlying mechanism for
this effect was suggested to be oncogenic viral infections
with concurrent suppressed immune surveillance of tumor
antigens.28 In addition, several nonviral risk factors,
including age, sex, race, and duration of dialysis have
been reported.29 Therefore, we chose to exclude patients
with viral hepatitis from our study population to minimize
bias toward cancer occurrence, although the true inci-
dence of post-transplant cancer could be underestimated.
Based on the substantial evidence suggesting that SRL has
antitumor properties, a primary strategy to reduce
cancer-related complications after renal transplantation
might be de novo therapy or early conversion to SRL (or
another mTOR inhibitor), although conversion to SRL has
not been proved effective in preventing recurrence of
malignant cancers except for those derived from the
skin.9,11
Female recipients of renal transplantation, in this study,
had a higher risk of post-transplant cancer, especially
urothelial carcinoma. Actually, in the general population,
the incidence of bladder cancer was similar in both sexes.30
Female sex was reported to be associated with higher grade
and stage of urothelial carcinoma, although the transplant
outcome of female patients (as we reported recently)
seemed better than that of our male patients.31e33 The
survival of female patients was lower after radical cys-
tectomy for bladder urothelial carcinoma.34 While the
contributing factors to worse prognosis of urothelial carci-
noma in females remain to be identified, immunosuppres-
sive therapy could possibly enhance the underlying
oncogenic processes in female patients and uncover the sex
differences in cancer biology. Future multicenter studies
would determine if the prognosis of female renal transplantrecipients with urothelial carcinoma is worse than that of
male patients.
The early use of SRL, which can improve renal function
and graft survival, for treating renal transplant recipients is
controversial.35 There was a latent predisposition to use
SRL in our study patients receiving transplants from
deceased donors, although donor type was not identified as
a significant factor for cancer occurrence in the univariate
analysis. The possibility of wound complications, delayed
graft function, and interstitial pneumonitis has concerned
both patients and transplant surgeons.36 In addition, SRL
exerts a paradoxical stimulatory effect on innate immunity;
thus, a CNI might be indispensable for suppressing acute
allograft rejection.37,38 Therefore, a regimen including low-
dose SRL and a CNI, proposed by us and Campistol et al,39
might be an appropriate early immunosuppressive therapy
for renal transplant recipients. However, it will be chal-
lenging to perform long-term randomized controlled trials,
even in large-volume transplant centers, to address the role
of immunosuppressive agents in post-transplant malig-
nancies.16 As such, retrospective caseecontrol cohorts are
the method of choice.
In conclusion, compared with conventional CNI-based
therapy, low-dose SRL combined with a CNI was associated
with reduced risk of post-transplant cancer in renal trans-
plant recipients. Accordingly, we propose a concept of de
novo cancer prevention using a low-dose proliferation
signal inhibitor, such as SRL, for renal transplant recipients.References
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